OKTO Launches: New Approach for Pain Management Reports NDIBA®

OKTO, is a a radiofrequency equipment with a stable 448kHz current perfect for treating acute and chronic pain, based on high-frequency neuromodulation of pain and metabolic stimulation of biological tissues.

“This hands-free equipment is a revolutionaly approach for pain management. It improves musculoskeletal and joint pain such as neuropathies, discopathies, osteoarthritis, osteochondrosis and post-traumatic injuries,” says Remco Schmitz, INDIBA CEO.

“Additionally, it will help clinics to save time and resources during consultation while offering the INDIBA guarantee of results on pain management,” says Diederik van Goor, ACTIV business unit leader.

At the heart of INDIBA Solutions, this device is targeted to Chiropractors, Physiotherapists, Pain Medicine, Physical therapists, Sports medicine specialists, Sports injury specialists, osteopaths, and Physical Rehab doctors.

The mechanism of action combines its scientifically proven enhancement of stem cell proliferation with the stimulation of neurovascular zones. OKTO’s eight active channels will allow professionals to work superficially or with full depth depending on the anatomical needs of each situation or pathology acting over the spine ganglions or over the peripheral nerve system giving an anthineuralgic and antineurithic effect.

SourceINDIBA®

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version